Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, Paula Maguire, Jiwon Yang, James G Keck, Laura Maher, Mark Graham, Martin F Kaiser, Emma Searle, Mark Sumeray

Blood (2024) 144 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2024-204734

Published: 2024

Journal Articles

PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Universal CD19 Chimeric Antigen Receptor T Cell Immunotherapy

Won Lee, Destanie Rose, Heather Gustafson, Meredith Jackson, Kamila Gwiazda, Joshua Gustafson, Mariliis Ott, Rebecca Gardner, James G Keck, Jiwon Yang

Blood (2023) 142 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2023-187223

Published: 2023

Journal Articles

Development of a Novel Solid Tumor-Bearing Humanized Animal Model for Simultaneously Evaluating the Toxicity and Efficacy of Bispecific T Cell Engager

Guoxiang Yang, Li-Chin Yao, Heather Gustafson, James G Keck, Mingshan Cheng

Blood (2023) 142 (Supplement 1): 6837.

https://doi.org/10.1182/blood-2023-187848

Published: 2023

Journal Articles

In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy

Won Lee, Destanie Rose, Mingshan Cheng, Heather Gustafson, Rebecca A Gardner, James G Keck, Jiwon Yang

Blood (2022) 140 (Supplement 1): 10267–10268.

https://doi.org/10.1182/blood-2022-158057

Published: 2022

Journal Articles

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Scott Smith, John Godwin, Jeffrey Lancet, Magda Melchert, Marsha Jones, James G. Keck, Lisa Meng, Gail L. Brown, Alan List

Blood (2009) 113 (26): 6533–6540.

https://doi.org/10.1182/blood-2009-01-176032

Published: 2009

Journal Articles

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

Mary R. Stofega, PhD, Mingshan Cheng, MD, Huiping Ma, MD, Lidia Sambucetti, PhD, James G. Keck, PhD, Gail L. Brown, MD, Danying Cai, PhD

Blood (2006) 108 (11): 1161.

https://doi.org/10.1182/blood.V108.11.1161.1161

Published: 2006

Journal Articles

.

Peter Dean Emanuel, MD, Zhuo Wang, PhD, Danying Cai, PhD, Mary R. Stofega, PhD, James G. Keck, PhD, Zeev Estrov, MD, Gail L. Brown, MD, Jose L. Ochoa-Bayona, MD, Natalie Callander, MD

Blood (2004) 104 (11): 2372.

https://doi.org/10.1182/blood.V104.11.2372.2372

Published: 2004

NARROW

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Universal CD19 Chimeric Antigen Receptor T Cell Immunotherapy

Development of a Novel Solid Tumor-Bearing Humanized Animal Model for Simultaneously Evaluating the Toxicity and Efficacy of Bispecific T Cell Engager

In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

.

Email alerts

ASH Publications

American Society of Hematology

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Universal CD19 Chimeric Antigen Receptor T Cell Immunotherapy

Development of a Novel Solid Tumor-Bearing Humanized Animal Model for Simultaneously Evaluating the Toxicity and Efficacy of Bispecific T Cell Engager

In Vivo PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Autologous and Allogeneic Chimeric Antigen Receptor T-Cell Immunotherapy

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only